Explore ways to combat exhaustion and feel re-energized throughout your day.
The study explores the potential of molecular hydrogen (H2) gas as a therapeutic substance for conditions characterized by fatigue, particularly Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and the “sequelae” of COVID-19.
H2 is thought to alleviate fatigue through its antioxidant and anti-inflammatory properties, as well as its ability to regulate gene expression. It scavenges reactive oxygen species (ROS) produced by mitochondria and modulates gene expression, potentially mitigating mitochondrial dysfunction, a key factor in fatigue disorders.
Animal studies and human clinical trials have demonstrated that H2 supplementation can increase exercise capacity, reduce fatigue indices, inhibit lactate accumulation, and improve antioxidant markers. These effects are believed to be mediated by H2’s antioxidative and anti-inflammatory actions.
Studies suggest that H2 may protect against mitochondrial dysfunction by scavenging mitochondria-generated ROS, thereby preventing oxidative damage and inflammation. This mechanism could contribute to its potential therapeutic effects in ME/CFS.
Yes, preliminary evidence suggests that H2 gas inhalation may improve symptoms and physical function in individuals experiencing “sequelae” of COVID-19, which share similarities with ME/CFS symptoms.
H2 gas is considered safe for use, as it is produced by intestinal bacteria and recognized as a food additive in various regions. Furthermore, clinical trials have demonstrated its efficacy and safety profile in different patient populations.
The study suggests that H2 gas may hold promise as a therapeutic intervention for fatigue-related conditions like ME/CFS and the “sequelae” of COVID-19. Further research is warranted to validate its efficacy and elucidate its mechanisms of action.
